High levels of pre-treatment CXCL13+ T cells are associated with pro-inflammatory macrophage activity and predict favorable responses in patients with triple-negative breast cancer receiving paclitaxel combined with a PD-L1 monoclonal antibody (31). This evidence concerns the gene CD274 and triple-negative breast carcinoma.